Early in vivo signaling profiles in MUC1-specific CD4+ T cells responding to two different MUC1-targeting vaccines in two different microenvironments

OncoImmunology

Volumn 2, Issue 3, 2013, Pages

  Reichenbach, Dawn K ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Phospho flow; Self antigen; Tolerance; Transgenic mice; Tumor antigen; Vaccine

Indexed keywords

DENDRITIC CELL VACCINE; IMMUNOLOGICAL ADJUVANT; MUCIN 1; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CELL SPECIFICITY; CELL SURVIVAL; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFICACY; FEASIBILITY STUDY; HOST CELL; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TRANSGENIC MOUSE; VACCINE PRODUCTION;

EID: 84886943278     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23429     Document Type: Article

References (33)

1. Weiner LM, Surana R, Wang S. Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 2010; 10:317-27; PMID:20414205; http://dx.doi.org/10.1038/nri2744.
2. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009; 15:5323-37; PMID:19723653; http://dx.doi.org/10.1158/1078-0432.CCR-09-0737.
3. Pardoll DM, Topalian SL. The role of CD4+ T cell responses in antitumor immunity. Curr Opin Immunol 1998; 10:588-94; PMID:9794842; http://dx.doi.org/10.1016/S0952-7915(98)80228-8.
4. Quezada SA, Simpson TR, Peggs KS, Merghoub T, Vider J, Fan X, et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 2010; 207:637-50; PMID:20156971; http://dx.doi.org/10.1084/jem.20091918.
5. Corthay A, Skovseth DK, Lundin KU, Røsjø E, Omholt H, Hofgaard PO, et al. Primary antitumor immune response mediated by CD4+ T cells. Immunity 2005; 22:371-83; PMID:15780993; http://dx.doi.org/10.1016/j.immuni.2005.02.003.
6. Soares MM, Mehta V, Finn OJ. Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 2001; 166:6555-63; PMID:11359807.
7. Turner MS, Cohen PA, Finn OJ. Lack of effective MUC1 tumor antigen-specific immunity in MUC1- transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol 2007; 178:2787-93; PMID:17312122.
8. Ryan SO, Turner MS, Gariépy J, Finn OJ. Tumor antigen epitopes interpreted by the immune system as self or abnormal-self differentially affect cancer vaccine responses. Cancer Res 2010; 70:5788-96; PMID:20587526; http://dx.doi.org/10.1158/0008-5472.CAN-09-4519.
9. Krutzik PO, Nolan GP. Intracellular phospho-protein staining techniques for flow cytometry: monitoring single cell signaling events. Cytometry A 2003; 55:61-70; PMID:14505311; http://dx.doi.org/10.1002/cyto.a.10072.
10. Krutzik PO, Irish JM, Nolan GP, Perez OD. Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 2004; 110:206-21; PMID:15047199; http://dx.doi.org/10.1016/j.clim.2003.11.009.
11. Krutzik PO, Nolan GP. Fluorescent cell barcoding in flow cytometry allows high-throughput drug screening and signaling profiling. Nat Methods 2006; 3:361-8; PMID:16628206; http://dx.doi.org/10.1038/nmeth872.
12. Perez OD, Krutzik PO, Nolan GP. Flow cytometric analysis of kinase signaling cascades. Methods Mol Biol 2004; 263:67-94; PMID:14976361.
13. Galligan CL, Siebert JC, Siminovitch KA, Keystone EC, Bykerk V, Perez OD, et al. Multiparameter phospho-flow analysis of lymphocytes in early rheumatoid arthritis: implications for diagnosis and monitoring drug therapy. PLoS One 2009; 4:e6703; PMID:19693272; http://dx.doi.org/10.1371/journal.pone.0006703.
14. Irish JM, Hovland R, Krutzik PO, Perez OD, Bruserud ø, Gjertsen BT, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004; 118:217-28; PMID:15260991; http://dx.doi.org/10.1016/j.cell.2004.06.028.
15. Lee AW, Sharp ER, O'Mahony A, Rosenberg MG, Israelski DM, Nolan GP, et al. Single-cell, phosphoepitope-specific analysis demonstrates cell type-and pathway-specific dysregulation of Jak/STAT and MAPK signaling associated with in vivo human immunodeficiency virus type 1 infection. J Virol 2008; 82:3702-12; PMID:18216116; http://dx.doi.org/10.1128/JVI.01582-07.
16. Mortarini R, Vegetti C, Molla A, Arienti F, Ravagnani F, Maurichi A, et al. Impaired STAT phosphorylation in T cells from melanoma patients in response to IL-2: association with clinical stage. Clin Cancer Res 2009; 15:4085-94; PMID:19509154; http://dx.doi.org/10.1158/1078-0432.CCR-08-3323.
17. Lu SX, Alpdogan O, Lin J, Balderas R, Campos-Gonzalez R, Wang X, et al. STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease. Blood 2008; 112:5254-8; PMID:18838616; http://dx.doi.org/10.1182/blood-2008-03-147322.
18. Gamper CJ, Powell JD. All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells. Front Immunol 2012; 3:312; PMID:23087689; http://dx.doi.org/10.3389/fimmu.2012.00312.
19. Shao Q, Ning H, Lv J, Liu Y, Zhao X, Ren G, et al. Regulation of Th1/Th2 polarization by tissue inhibitor of metalloproteinase-3 via modulating dendritic cells. Blood 2012; 119:4636-44; PMID:22415751; http://dx.doi.org/10.1182/blood-2011-08-376418.
20. Perkey E, Miller RA, Garcia GG. Ex vivo enzymatic treatment of aged CD4 T cells restores cognate T cell helper function and enhances antibody production in mice. J Immunol 2012; 189:5582-9; PMID:23136198; http://dx.doi.org/10.4049/jimmunol.1200487.
21. Awasthi A, Mathur R, Khan A, Joshi BN, Jain N, Sawant S, et al. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J Exp Med 2003; 197:1037-43; PMID:12695487; http://dx.doi.org/10.1084/jem.20022033.
22. Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, et al. STAT3 regulates cytokinemediated generation of inflammatory helper T cells. J Biol Chem 2007; 282:9358-63; PMID:17277312; http://dx.doi.org/10.1074/jbc.C600321200.
23. Harris TJ, Grosso JF, Yen HR, Xin H, Kortylewski M, Albesiano E, et al. Cutting edge: An in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 2007; 179:4313-7; PMID:17878325.
24. Stritesky GL, Muthukrishnan R, Sehra S, Goswami R, Pham D, Travers J, et al. The transcription factor STAT3 is required for T helper 2 cell development. Immunity 2011; 34:39-49; PMID:21215659; http://dx.doi.org/10.1016/j.immuni.2010.12.013.
25. Turner MS, Kane LP, Morel PA. Dominant role of antigen dose in CD4+Foxp3+ regulatory T cell induction and expansion. J Immunol 2009; 183:4895-903; PMID:19801514; http://dx.doi.org/10.4049/jimmunol.0901459.
26. Krutzik PO, Hale MB, Nolan GP. Characterization of the murine immunological signaling network with phosphospecific flow cytometry. J Immunol 2005; 175:2366-73; PMID:16081807.
27. Zell T, Khoruts A, Ingulli E, Bonnevier JL, Mueller DL, Jenkins MK. Single-cell analysis of signal transduction in CD4 T cells stimulated by antigen in vivo. Proc Natl Acad Sci U S A 2001; 98:10805-10; PMID:11535838; http://dx.doi.org/10.1073/pnas.191567898.
28. Crellin NK, Garcia RV, Levings MK. Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 2007; 109:2014-22; PMID:17062729; http://dx.doi.org/10.1182/blood-2006-07-035279.
29. Siegel AM, Heimall J, Freeman AF, Hsu AP, Brittain E, Brenchley JM, et al. A critical role for STAT3 transcription factor signaling in the development and maintenance of human T cell memory. Immunity 2011; 35:806-18; PMID:22118528; http://dx.doi.org/10.1016/j.immuni.2011.09.016.
30. Noubade R, Krementsov DN, Del Rio R, Thornton T, Nagaleekar V, Saligrama N, et al. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 2011; 118:3290-300; PMID:21791428; http://dx.doi.org/10.1182/blood-2011-02-336552.
31. Vlad AM, Muller S, Cudic M, Paulsen H, Otvos L Jr., Hanisch FG, et al. Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 2002; 196:1435-46; PMID:12461079; http://dx.doi.org/10.1084/jem.20020493.
32. Schulz KR, Danna EA, Krutzik PO, Nolan GP. Single-cell phospho-protein analysis by flow cytometry. Current protocols in immunology/edited by John E Coligan [et al], 2012:Unit 8.17.1-20.
33. Krutzik PO, Clutter MR, Nolan GP. Coordinate analysis of murine immune cell surface markers and intracellular phosphoproteins by flow cytometry. J Immunol 2005; 175:2357-65; PMID:16081806